Two weeks after filing to go public, Grail has instead accepted an $8bn acquisition offer from Illumina, which had spun off the cancer diagnostics technology developer five years ago.
US-based medical diagnostics technology Grail agreed to an $8bn acquisition by genomics technology producer Illumina, which had originally spun out the former, according to a regulatory filing on Sunday. Grail will receive $3.5bn in cash and another $4.5bn in stock. The two companies have agreed a deadline of December 20 to close the transaction, following…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Thierry Heles
Thierry Heles is the editor of Global University Venturing, host of the Talking Tech Transfer interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
